<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423579</url>
  </required_header>
  <id_info>
    <org_study_id>P04039</org_study_id>
    <nct_id>NCT00423579</nct_id>
  </id_info>
  <brief_title>The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of Administration of Ezetimibe/Simvastatin Tablet 10/20 mg Versus Doubling the Dose of Simvastatin 20 mg [Simvastatin 40 mg] in Subjects With Primary Hypercholesterolemia and Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to compare the efficacy, safety, and tolerability of
      ezetimibe/simvastatin 10/20 mg when administered daily versus doubling the dose of
      simvastatin to 40 mg in patients with hypercholesterolemia and coronary heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2006</start_date>
  <completion_date type="Actual">March 1, 2008</completion_date>
  <primary_completion_date type="Actual">March 1, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>Percentage change in LDL C from baseline to endpoint after 6 weeks of treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Coronary Disease</condition>
  <arm_group>
    <arm_group_label>Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe/Simvastatin placebo + Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe/Simvastatin 10/20 mg</intervention_name>
    <description>1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks</description>
    <arm_group_label>Ezetimibe/Simvastatin 10/20 mg + Simvastatin placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin 40 mg</intervention_name>
    <description>1 tablet containing 40 mg of simvastatin per day for 6 weeks</description>
    <arm_group_label>Ezetimibe/Simvastatin placebo + Simvastatin 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have documented coronary heart disease (CHD). For the purposes of this
             study, CHD will include one or more of the following features: documented stable
             angina (with evidence of ischemia on exercise testing); history of myocardial
             infarction; history of percutaneous coronary intervention [PCI] (primarily PCI with or
             without stent placement); symptomatic peripheral vascular disease (claudication);
             documented history of atherothrombotic cerebrovascular disease; and/or documented
             history of unstable angina or non-Q wave myocardial infarction.

          -  Subjects must demonstrate their willingness to participate in the study and comply
             with its procedures by signing a written informed consent.

          -  History of myocardial infarction (heart attack).

          -  Subjects must be &gt;= 18 years and &lt;= 75 years of age.

          -  Subjects must have an LDL-C concentration &gt;= 2.6 mmol/L (100 mg/dL) to &lt;= 4.1 mmol/L
             (160 mg/dL) at the time of randomization (Visit 3/Baseline Visit).

          -  Subjects must have triglyceride concentrations of &lt; 3.99 mmol/L (350 mg/dL) at (Visit
             3 Baseline Visit).

          -  Subject must be currently taking simvastatin 20 mg daily.

          -  Subjects must have liver transaminases (ALT [alanine aminotransferase], AST [aspartate
             aminotransferase]) &lt; 50% above the upper limit of normal, with no active liver
             disease, and CK (creatine kinase) &lt; 50% above the upper limit of normal at Visit 3
             (Baseline Visit).

          -  Clinical laboratory tests (complete blood count [CBC], blood chemistries, urinalysis)
             must be within normal limits or clinically acceptable to the investigator at Visit 3
             (Baseline Visit).

          -  Subjects must have maintained a cholesterol-lowering diet and exercise program for at
             least 4 weeks prior to the study and be willing to continue the same diet and exercise
             program during the study.

          -  Subjects must report a stable weight history for at least 4 weeks prior to entry into
             study at Visit 3 (Baseline Visit).

          -  Women receiving hormonal therapy, including hormone replacement, any estrogen
             antagonist/agonist, or oral contraceptives, must have been maintained on a stable dose
             and regimen for at least 8 weeks and be willing to continue the same regimen for the
             duration of the study.

          -  Women of childbearing potential (includes women who are less than 1 year
             postmenopausal and women who become sexually active) must be using an acceptable
             method of birth control (e.g., hormonal contraceptive, medically prescribed
             intrauterine device [IUD], condom in combination with spermicide) or be surgically
             sterilized (e.g., hysterectomy or tubal ligation).

          -  Subjects must be free of any clinically significant diseases other than hyperlipidemia
             or coronary heart disease that would interfere with study evaluations.

          -  Subjects must understand and be able to adhere to the dosing and visit schedules, and
             must agree to remain on their cholesterol-lowering diet and their exercise regimen for
             the duration of the study.

        Exclusion Criteria:

          -  Subjects whose body mass index (BMI = weight [kg]/height2 [m]) is &gt;= 35 kg/m^2 at
             Visit 3 (Baseline Visit).

          -  Subjects who consume &gt; 14 alcoholic drinks per week. (A drink is: a can of beer, glass
             of wine, or single measure of spirits).

          -  Any condition or situation which, in the opinion of the investigator, might pose a
             risk to the subject or interfere with participation in the study.

          -  Women who are pregnant or nursing.

        Exclusion Criteria: subjects who have the following medical conditions:

          -  Congestive heart failure defined by New York Heart Association (NYHA) as Class III or
             IV.

          -  Uncontrolled cardiac arrhythmia.

          -  Myocardial infarction, acute coronary insufficiency, coronary artery bypass surgery,
             or angioplasty within 3 months of Visit 3 (Baseline Visit).

          -  Unstable or severe peripheral artery disease within 3 months of Visit 3 (Baseline
             Visit).

          -  Newly diagnosed or currently unstable angina pectoris (chest pain).

          -  Uncontrolled hypertension (treated or untreated) with systolic blood pressure &gt; 160 mm
             Hg or diastolic &gt; 100 mm Hg at Visit 3 (Baseline Visit).

          -  Type I or Type II diabetes mellitus.

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins, i.e., secondary causes of hyperlipidemia, such as secondary
             hypercholesterolemia due to hypothyroidism (thyroid stimulating hormone [TSH] above
             upper limit of normal) at Visit 3. Subjects with a history of hypothyroidism who are
             on a stable therapy of thyroid hormone replacement for at least 6 weeks are eligible
             for enrollment if TSH levels are within normal limits at Visit 3 (Baseline Visit).

          -  Impaired renal function (creatinine &gt; 2.0 mg/dL) or nephrotic syndrome at Visit 3
             (Baseline Visit).

          -  Disorders of the hematologic, digestive, or central nervous systems including
             cerebrovascular disease and degenerative disease that would limit study evaluation or
             participation.

          -  Known Human Immunodeficiency Virus (HIV) positive.

          -  Cancer within the past 5 years (except for successfully treated basal and squamous
             cell carcinomas).

          -  History of mental instability, drug/alcohol abuse within the past 5 years, or major
             psychiatric illness not adequately controlled and stable on pharmacotherapy.

        Exclusion Criteria: subjects who are on any of the following concomitant medications:

          -  Subjects who have not observed the designated wash-out period for any of the
             prohibited medications.

          -  Subjects who have not stopped taking various prohibited medications for a minimum
             period of time before Visit 3, including amiodarone hydrochloride (6 months) and
             probucol (12 months).

          -  Subjects currently consuming large amounts of grapefruit juice (&gt; 1 liter/day).

          -  Oral corticosteroids, unless used as replacement therapy for pituitary/adrenal disease
             and the subject is on a stable regimen for at least 6 weeks prior to Visit 3 (Baseline
             Visit).

          -  Subjects who are currently using cardiovascular medication (e.g. antihypertensive,
             antiarrhythmic) and have not been on a stable regimen for at least 6 weeks prior to
             Visit 3 (Baseline Visit) and it is expected to change during the study.

          -  Subjects who are currently using psyllium, other fiber-based laxatives, and/or any
             other over-the-counter (OTC) therapy known to affect serum lipid levels (phytosterol
             margarine), and have not been on a stable regimen for at least 5 weeks prior to study
             entry Visit 3 (Baseline Visit) and who do not agree to remain on this regimen
             throughout the study.

          -  Subject who are currently using orlistat or sibutramine.

          -  Subjects who are currently using amiodarone hydrochloride.

          -  Subjects who are currently using danazol.

          -  Subjects who are currently using coumarin anticoagulants (warfarin).

          -  Subjects who are using (at the Screening Visit / Visit 1) any statin other than
             simvastatin 20 mg, or ezetimibe alone or in combination with any statin (including the
             fixed combination with simvastatin).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <results_first_submitted>March 19, 2009</results_first_submitted>
  <results_first_submitted_qc>July 16, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2009</results_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Visits 1 and 2 were for screening, combined if wash-out not required. One ineligible subject mistakenly received assignment at Visit 2 and was removed. The subject did not receive treatment. Actual enrollment: 120 subjects. Intent-to-treat (ITT) population included only evaluable subjects; as such analysis based on 112 subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ezetimibe/Simvastatin 10/20 mg + Simvastatin Placebo</title>
          <description>Subjects in the Intent-to-Treat Population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment</description>
        </group>
        <group group_id="P2">
          <title>Ezetimibe/Simvastatin Placebo + Simvastatin 40 mg</title>
          <description>Subjects in the Intent-to-Treat population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60">61 enrolled, however one subject was ineligible and was removed.</participants>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56">These 56 subjects were the Intent-to-Treat population. Analysis based on ITT population.</participants>
                <participants group_id="P2" count="56">These 56 subjects were the Intent-to-Treat population. Analysis based on ITT population.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Diagnosis of diabetes</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ezetimibe/Simvastatin 10/20 mg + Simvastatin Placebo</title>
          <description>Subjects in the Intent-to-Treat Population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment</description>
        </group>
        <group group_id="B2">
          <title>Ezetimibe/Simvastatin Placebo + Simvastatin 40 mg</title>
          <description>Subjects in the Intent-to-Treat population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean age based on Intent-to-Treat population.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.3" spread="8.4"/>
                    <measurement group_id="B2" value="62.1" spread="7.8"/>
                    <measurement group_id="B3" value="61.7" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Gender totals based on Intent-to-Treat population.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks</title>
        <description>Percentage change in LDL C from baseline to endpoint after 6 weeks of treatment.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>Intent-to-treat population only.</population>
        <group_list>
          <group group_id="O1">
            <title>Ezetimibe/Simvastatin 10/20 mg + Simvastatin Placebo</title>
            <description>Subjects in the Intent-to-Treat Population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment</description>
          </group>
          <group group_id="O2">
            <title>Ezetimibe/Simvastatin Placebo + Simvastatin 40 mg</title>
            <description>Subjects in the Intent-to-Treat population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks</title>
          <description>Percentage change in LDL C from baseline to endpoint after 6 weeks of treatment.</description>
          <population>Intent-to-treat population only.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.5" spread="9.5"/>
                    <measurement group_id="O2" value="-11.9" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0000</p_value>
            <method>Student's t test for independent data</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-14.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-18.9</ci_lower_limit>
            <ci_upper_limit>-10.1</ci_upper_limit>
            <estimate_desc>Difference in percentage change in mean LDL-C values (change from baseline to week 6) between the two treatment groups. (Ezetimibe [EZ]/Simvastatin [S] [10/20mg] + S [placebo] group minus the EZ/S [10mg/placebo] + S [40mg] group)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ezetimibe/Simvastatin 10/20 mg + Simvastatin Placebo</title>
          <description>Subjects in the Intent-to-Treat Population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin 10/20 mg. The second tablet is simvastatin placebo. Subjects will receive a maximum of 6 weeks of treatment</description>
        </group>
        <group group_id="E2">
          <title>Ezetimibe/Simvastatin Placebo + Simvastatin 40 mg</title>
          <description>Subjects in the Intent-to-Treat population. Subjects will receive 2 tablets. The first tablet is Ezetimibe/Simvastatin placebo. The second tablet is simvastatin 40 mg. Subjects will receive a maximum of 6 weeks of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Transient Ischemic Attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator shall not publish or publicly present the study results without prior written authorization from the sponsor, except for dispositions in the Ministerial Circular n. 6 dated 02 SEP 2002. The investigator shall notify the sponsor in writing of any publication submission or presentation reporting results of the study 30 days prior to submission or presentation to permit sponsor review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

